The research of the treatment to type 2 diabetes mellitus (T2DM) by lixisenatide

Jiajing HAN,Bingmi LIU,Ye CHEN,Yu LIU
DOI: https://doi.org/10.14066/j.cnki.cn21-1349/r.2018.05.016
2018-01-01
Abstract:Objective To study the progress of clinical research of lixisenatide ( Lyxumia) as one of the glucagon-like peptide ( GLP) -1 receptor agonists which is used to treat T2 DM, thus provides references and helps to the further research. Methods Based on the analyzing and tiding of published literatures, the mechanism of action and clinical research progress of lixisenatide were described. Results Lixisenatide as a newmember of glucagon-like peptide ( GLP) -1 receptor agonist to defend T2 DM, it showed excellent properties in increasing insulin secretion, inhibiting of glucagon secretion and controlling the level of fasting and postprandial plasma glucose. In addition, comparing to other glucagon-like peptide ( GLP) -1 receptor agonists, lixisenatide could also reduce the risk of cardiovascular diseases. Conclusions The clinical program proves that lixisenatide has the good safety and tolerability, it can significantly reduce the value of Hb A1 c and substantialy control fasting and postprandial plasma glucose within a normal level. Meanwhile, it would not lead to an obviously increase in body weight and reduce the risk of hypoglycemia, therefore, it has a bright future in defending T2 DM.
What problem does this paper attempt to address?